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Abstract 
Protein phosphorylation plays a determining role in the regulation of chondrogenesis in vitro. 
While signalling pathways governed by protein kinases including PKA, PKC, and mitogen-
activated protein kinases (MAPK) have been mapped in great details, published data relating 
to the specific role of phosphoprotein phosphatases (PPs) in differentiating 
chondroprogenitor cells or in mature chondrocytes is relatively sparse. This review discusses 
the known functions of Ser/Thr-specific PPs in the molecular signalling pathways of 
chondrogenesis. PPs are clearly equally important as protein kinases to counterbalance the 
effect of reversible protein phosphorylation. Of the main Ser/Thr PPs, some of the functions 
of PP1, PP2A and PP2B have been characterised in the context of chondrogenesis. While 
PP1 and PP2A appear to negatively regulate chondrogenic differentiation and maintenance of 
chondrocyte phenotype, calcineurin is an important stimulatory mediator during 
chondrogenesis but becomes inhibitory in mature chondrocytes. Furthermore, PPs are 
implicated to be important mediators during the pathogenesis of osteoarthritis that makes 
them potential therapeutic targets to be exploited in the close future. Among the many yet 
unexplored targets of PPs, modulation of plasma membrane ion channel function and 
participation in mechanotransduction pathways are emerging novel aspects of signalling 
during chondrogenesis that should be further elucidated. Besides the regulation of cellular ion 
homeostasis, other potentially important novel roles for PPs during the regulation of in vitro 
chondrogenesis are discussed. 
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Abbreviations: 
ADAMTS, “A Disintegrin And Metalloproteinase with Thrombospondin Motifs”; BMP, 
bone morphogenic protein; CaMK, Ca2+/calmodulin-dependent protein kinase; CaN, 
calcineurin; CNA, CNB, calcineurin catalytic (A) and regulatory (B) subunits; COX, 
cyclooxygenase; CREB, cAMP response element binding protein; CsA, cyclosporine A;  
ECM, extracellular matrix; ERK1/2, extracellular signal-related kinase 1/2; FGF; fibroblast 
growth factor; GADD34, growth arrest and DNA damage protein-34; HDAC, histone 
deacetylase; IP3R, inositol trisphosphate receptor; MAPK, mitogen-activated protein kinase; 
MEF, myocyte enhancer factor; MMP, matrix metalloproteinase; NFAT, nuclear factor of 
activated T lymphocytes; NF-κB, nuclear factor-kappa B; NO, nitrogen oxide; OA, 
osteoarthritis; OKA, okadaic acid; PACAP, pituitary adenylate cyclase activating 
polypeptide; PK, protein kinase; PKA, PKC, protein kinase-A, protein kinase C; PP1, PP2A, 
PP2B, protein phosphatase 1, 2A, 2B; PP, phosphoprotein phosphatase; PTHrP, parathyroid 
hormone related peptide; ROS, reactive oxygen species; RyR, ryanodine receptor; 
SAPK/JNK, stress-activated protein kinase/c-jun N-terminal kinase; SOCE, store-operated 
Ca2+ entry; SSC, synovial stromal cell; TGF-β, transforming growth factor beta; TNF, tumour 
necrosis factor; TRPV, transient receptor potential vanilloid; TβR, TGF-β receptor 
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1. Introduction 
The formation and maturation of tissues that comprise the musculoskeletal system in 
the developing embryo is a truly enigmatic process. Formed as early as week 4 in the human 
embryo, the undifferentiated embryonic connective tissue (mesenchyme) that eventually 
gives rise to the skeleton develops primarily from components of mesoderm [1]. In addition, 
cartilaginous parts of the cranium are derivatives of ectomesenchyme of neural crest origin. It 
is from this mesenchyme that the histogenesis of cartilage commences at condensed sites 
called chondrification centres that appear starting from week 5; mesenchymal cells 
committed towards the osteochondrogenic lineage differentiate into chondroblasts and start to 
secrete the specialised components of the cartilage extracellular matrix (ECM). 
The transition from elongated mesenchymal cells to ovoid chondroblasts is a highly 
complex procedure that involves changes in gene expression [2], activation and/or inhibition 
of various signalling pathways [3, 4], alterations in cytosolic Ca2+ concentration [5, 6], and 
differentiation stage-dependent expression and function of plasma membrane ion channels [7, 
8]. Because of the complexity of programmed alterations necessary for chondrogenic 
differentiation, the details of this process are still incompletely understood. Besides 
elucidating the molecular mechanism that drives chondrogenesis, cartilage research is also 
aimed at providing a better understanding of pathological processes that affect the normal 
functions of this tissue, causing debilitating disorders. Osteoarthritis (OA) is the most 
prevalent degenerative joint disease and source of chronic pain for millions of people 
worldwide. Causes of OA are complex with interplay between mechanical, genetic and 
lifestyle factors [9]. At the late stages of the disease, OA is characterised by degradation of 
articular cartilage, synovial inflammation, and osteophyte formation [10]. At present, there 
are no effective disease modifying drugs available that are specifically targeted to OA; 
therefore, there is a pressing need to identify and develop novel therapeutic agents to halt or 
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even reverse disease progression [11]. Lack of effective and specific drugs against OA are at 
least partially a consequence of the fact that the molecular nature of the disease is not 
adequately known.   
This review article focuses on the role of protein phosphorylation, the most widespread 
mechanism for posttranslational protein modification to modulate cellular behaviour, with 
special emphasis on current knowledge regarding the involvement of phosphoprotein 
phosphatases (PPs) in the process of chondrogenesis and the pathogenesis of OA. 
 
2. Reversible protein phosphorylation is a key regulator of chondrogenesis 
Reversible posttranslational modification of proteins provides an extremely efficient 
means of rapid regulation of protein activity without the immediate need for de novo protein 
synthesis or targeted protein degradation. Activity of a vast number of cellular proteins is 
regulated by phosphorylation at select Tyr and/or Ser/Thr residues by Tyr and/or Ser/Thr-
specific protein kinases (PK). In particular, approximately one-third of all proteins in a given 
cell have been shown to be phosphorylated at a given time; the complement of phospho-
proteins in a cell is referred to as the phosphoproteome [12]. In a study that mapped 
phosphorylation sites in HeLa cells, phospho-Tyr sites were the least abundant (1.8%), 
followed by phospho-Thr sites (11.8%), and Ser residues proved to be the most frequently 
phosphorylated sites (86.4%) [13].  
A wide array of cellular processes and functions ranging from metabolism, cellular 
homeostasis, migration, cell division and proliferation, differentiation, and even pathological 
processes such as tumourigenesis are controlled by reversible protein phosphorylation [14]. 
The actual level of phosphorylated cellular proteins is determined by a balance between PKs 
and PPs. To carry out the immense amount of modifications, approximately 500 PKs have 
been identified in the human genome, of which ~90 were specific for Tyr residues, and the 
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remaining 428 kinases preferentially phosphorylate Ser/Thr residues [15], which correlates 
well with the relative abundance of the phospho-Ser/Thr sites described above. Given the 
predominance of phosphorylation and dephosphorylation at Ser/Thr residues, and the 
relatively understudied role of Tyr-specific phosphatases in cartilage formation, this review 
article focuses on Ser/Thr-specific PPs in chondrogenesis.  
Since attaching a phosphate group released from the hydrolysis of ATP to select 
Ser/Thr residues of protein substrates is a fairly simple process, the structural biochemistry of 
the PK superfamily is likewise simple; they all share a basic structure and operate with 
similar mechanisms [16]. At the same time, PKs can regulate diverse biological pathways; 
this is achieved by various activation mechanisms and their multiple downstream signalling 
targets. Many Ser/Thr-specific PKs have been reported over the previous decades that proved 
to be essential regulators of the formation of chondroblasts and then chondrocytes. In the 
following section we provide a brief overview of main Ser/Thr-specific PK families reported 
to control various steps of chondrogenesis. 
 
2.1. Ser/Thr-specific PKs regulate chondrogenesis 
Given that chondrogenesis is a highly complex process, it is not surprising that all main 
PK families have been reported to play a fundamental role in its molecular regulation. Cyclic 
AMP-dependent protein kinase (PKA) activity detectable in cell homogenates of developing 
limb buds of early chicken embryos [17] was found to enhance in vitro chondrogenesis and to 
increase phosphorylation of the cAMP response element binding protein (CREB) [18]. 
Unlike PKA, the collection of enzymes that constitutes the protein kinase C (PKC) subfamily 
is traditionally subdivided into classic, novel and atypical PKCs. PKC activity has also been 
detected in chondrogenic micromass cultures [19], and a wide array of functions has been 
associated with PKC isoenzymes since then. These include, but are not limited to, actin 
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cytoskeleton remodelling, cell adhesion molecules, ion channel activity, and modulation of 
other signalling pathways (reviewed in [4]). PKA and PKC activities have been proved to be 
closely linked; PKA, in particular, regulates chondrogenesis by modulating N-cadherin 
expression via activating PKCα at the early stages of chondrogenesis [20]. 
The three major mitogen-activated protein kinase (MAPK) cascades, i.e. the 
extracellular signal-regulated kinase 1/2 (ERK1/2), p38, and c-jun N-terminal kinase (JNK) 
pathways, are quintessential regulators of chondrogenesis (for an excellent recent review, see 
[3]). Consisting of a cascade of protein kinases, Raf, MAPK/ERK kinase (MEK) and 
ERK1/2, the ERK pathway mediates the effects of growth factors and cytokines through a 
plethora of downstream signalling pathways during chondrogenesis. While p38 clearly 
stimulates chondrogenesis in all experimental models studied [21, 22], the ERK1/2 pathway 
has been reported to be both negative [23, 24] and positive regulator [25, 26] of chondrogenic 
differentiation, depending on the species, the differentiation stage, the embryonic origin of 
chondroprogenitor cells, and probably the context of other concurrently active/blocked 
signalling mechanisms [3]. Likewise, both chondrogenesis-promoting [27] and inhibitory 
[28] effects for the JNK pathway have been established. 
The family of Ca2+/calmodulin-dependent protein kinases (CaMK) consists of 4 
multifunctional Ser/Thr PKs; CaMKII (also known as eEF2-kinase) and the CaMK cascade 
in which CaMK kinase (CaMKK) phosphorylates and activates CaMKI and CaMKIV [29]. 
This pathway is of particular importance since a plethora of messages encoded by specific 
alterations in the amplitude, frequency and special distribution of cytosolic Ca2+ 
concentration is deciphered by these Ca2+-calmodulin dependent kinases [30]. CaMKs have 
been implicated to mediate the effects of mechanical forces in chondrocytes [31] and are also 
involved in modulating hypertrophic gene expression (e.g. Runx2, Col10a1) during terminal 
differentiation of chondrocytes [32]. Table 1 summarises the main PK families with a proven 
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role in chondrogenesis or mature chondrocytes. 
 
3. Ser/Thr-specific phosphoprotein phosphatases (PPs) 
For protein phosphorylation to be reversible and adjustable to the actual needs of the 
organism and/or cell, the actions of both phosphorylation (i.e. PKs) and dephosphorylation 
(i.e. PPs) are needed to be versatile and exhibit similar levels of complexity. However, in 
contrast to the high number (more than 500) of PKs, there are only 107 putative Tyr 
phosphatases, and even less (approx. 30) Ser/Thr-specific PPs encoded in the human genome, 
albeit some of them have dual specificity [15]. It is therefore evident that PPs cannot be 
matched with PKs on a one-to-one basis; instead, since PPs are obligate multimeric enzymes, 
they apply a combinatorial approach in which a limited number of catalytic subunits are 
combined with a great variety of regulatory subunits to achieve specificity. In fact, there are 
only 13 genes that encode catalytic PP subunits in the human genome, which can associate 
with more than 100 different regulatory subunits that are the major determinants of substrate 
specificity and subcellular localisation [33]. Moreover, instead of sharing structural as well as 
operational similarities just like kinases, PPs are characterised by diverse structure, 
biochemistry, and even active hydrolytic sites. Based on their reaction mechanisms, Ser/Thr 
PPs are conventionally subdivided into three major families: (1) the aspartate-based 
phosphatases such as FCP/SCP which is involved in dephosphorylation of RNA polymerase 
II C-terminal domain; (2) metal ion-dependent (Mg2+ or Mn2+) protein phosphatases (PPMs) 
such as PP2C and pyruvate dehydrogenase phosphatase; and (3) phosphoprotein 
phosphatases (PPs) [14, 15]. In this review article, we will now focus on the third group in 
the context of chondrogenesis. 
PPs are responsible for dephosphorylating the vast majority of phospho-Ser/Thr 
residues in cells. PPs, with only a few exceptions, are multi-subunit complexes consisting of 
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a catalytic subunit and several regulatory subunits; each catalytic subunit is allowed to 
associate with a great variety of regulatory subunits to maintain specificity. The PP family of 
phosphatases is further subdivided into protein phosphatase 1 (PP1), PP2A, PP2B (also 
known as calcineurin or PP3), PP4, PP5, and PP6. For an extensive recent review, please see 
[16]. In the following section, individual PPs are highlighted with their distinct roles in 
regulating various steps of chondrogenesis, as well as signalling pathways in mature 
chondrocytes. 
 
4. Protein phosphatase 1 (PP1) 
Ubiquitously expressed in all eukaryotic cells, PP1 is involved in a host of cellular 
processes including, but not limited to, cell division, cytoskeletal rearrangement, cellular 
metabolism, and regulation of ion channel function [34]. Functional PP1 holoenzymes consist 
of a highly conserved ~35 kDa catalytic subunit (C) associated with a regulatory (R) subunit 
that is responsible for subcellular localisation and determines substrate specificity. While 
there are only a few genes (PP1cα, PP1cβ/δ, and PP1cγ) that code for catalytic subunit 
proteins, more than a hundred putative R subunits have been identified [35]. The naturally 
occurring toxins okadaic acid (OKA) and microcystin are potent inhibitors of the catalytic 
subunit of both PP1 and PP2A [36, 37] and are thus widely used to study the role of these 
phosphatases in various contexts. 
 
4.1. Initial studies using OKA as a phosphatase inhibitor 
Originally isolated from the marine sponge Halichondria okadai, OKA exerts 
inhibitory effects on PP1 and PP2A at different concentrations. During in vitro activity assay 
conditions, PP2A is completely inhibited by 1 nM OKA, whereas PP1 is unaffected at this 
concentration for its IC50 value is an order of magnitude higher (10–15 nM) [38]. Its fairly 
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good plasma membrane permeability makes it suitable to inhibit PP1 and/or PP2A activity in 
cellular systems. When 30 nM OKA was applied to cultures of primary human articular 
chondrocytes, a significant upregulation of cyclooxygenase-2 (COX-2) mRNA was detected, 
accompanied by increased COX-2 enzyme synthesis [39]. At the same time, enhanced 
phosphorylation of the CREB-1 transcription factor, an important co-activator of cAMP-
responsive genes was observed, suggesting that PP1/PP2A may be important mediators in 
dephosphorylation of this protein. They also found that OKA suppressed the activity of 
ERK1/2, implicating that PP1/PP2A was a positive regulator of this pathway; by contrast, 
dramatic increase in SAPK/JNK expression and activity was identified in OKA-treated 
cultures of mature chondrocytes (Fig. 1). In that study, however, PP1 and PP2A activities 
have not been assayed separately, and it is therefore impossible to infer independent roles for 
PP1 and PP2A. 
The first report on the presence and activity of PP1 in chondrogenic cells dates back to 
2001 by our laboratory; in this work, OKA was applied to micromass cultures established 
from embryonic chick limb buds [40]. In vitro enzyme activity assays using 32P-labelled 
phosphorylase revealed that PP1 activity remained steady during the course of 
chondrogenesis, indicating its rather general role. While administration of OKA at lower 
concentrations into the culture medium (2–5 nM; i.e. when PP1 is largely unaffected) caused 
slight alterations only, application at 10 or 20 nM (i.e. inhibition of both PP1 and PP2A could 
be expected based on cell-free assays according to [38]) resulted in a significant 
chondrogenesis-stimulating effect. However, in vitro PP1 enzyme activity assays revealed 
unchanged PP1 activity in cell lysates of cultures previously treated with 20 nM OKA. 
Therefore, no direct conclusions could be drawn from this study regarding the functions of 
PP1 during chondrogenesis. It is of note, however, that the above IC50 values of OKA were 
established in cell-free systems with purified enzymes [38], hence might not be directly 
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applicable to cell culture systems; i.e. higher concentrations might be necessary to achieve 
half inhibition of either PP1 or PP2A. 
 
4.2. Further roles of PP1 in chondrocytes 
In spite of its pleiotropic effects and ubiquitous expression, further data on the role of 
PP1 in chondrocytes is surprisingly scarce. Transforming growth factor beta (TGF-β) 
signalling is a well-known inducer of chondrogenesis in mesenchymal cells [41]. TGF-β 
elicits cellular responses ranging from proliferation, differentiation, and apoptosis through 
binding to their specific type I and II kinase receptors TβRI and TβRII, which in turn induce 
phosphorylation of specific Ser/Thr residues. Once activated, TβRI phosphorylates Smad 
proteins, a subclass of unique intracellular signalling molecules, which then translocate into 
the nucleus and regulate transcription of target genes such as Col2a1 [42]. However, 
surprisingly little is known about the negative regulation of this pathway by PPs. In a study 
wherein a human chondrocyte cDNA library was screened in a yeast two-hybrid system, the 
authors demonstrated that Smad7 interacts with the growth arrest and DNA damage protein 
(GADD34), one of the many regulatory/targeting subunits of the PP1 holoenzyme, and that 
the formation of this holoenzyme mediated by TGF-β-induced Smad7 acts as a negative 
feedback in TGF-β signalling by dephosphorylating TβRI [43] (Fig. 1). These results indicate 
an important regulatory mechanism by which TGF-β may control the development and 
differentiation of various cell types, although this signalling pathway has not been verified in 
chondrocytes in vivo. 
 
4.3. PP1 in osteoarthritis 
As already mentioned, there is an urgent need for identifying novel therapeutic options 
for the treatment of OA. While PPs seem to be promising drug targets, their involvement in 
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the pathologic processes of OA has only been marginally investigated. The first study in this 
field established that 48-hour-long treatment with high concentrations of OKA (50 or 100 
nM) elicited apoptotic cell death of OA-affected cartilage-derived human chondrocytes via 
caspase-3 activation [44]. The authors speculated that the observed effects could be attributed 
to PP1/PP2A inhibition; however, the extremely high concentration of OKA used in this 
study might have caused cytotoxic effects irrespective of PP inhibition; thus the role of PP1 
in OA remains elusive. 
In summary, given its pleiotropic effects and multiple targets, experimental data 
concerning specific roles of PP1 during chondrogenesis, as well as in mature or inflammatory 
chondrocytes is surprisingly scarce. This is probably because the wide array of processes 
with the involvement of PP1 makes it hard to study this PP using conventional techniques. 
Fig. 1 summarises the known functions of PP1 in chondrogenic cells and in mature 
chondrocytes. 
 
5. Protein phosphatase 2A (PP2A) 
One of the most abundant cytosolic proteins, PP2A catalytic subunits can account for 
0.1% of total cellular proteins in certain cell types [33]. Accordingly, PP2A is vital in 
regulating development, cell cycle, proliferation and cell death, mobility, cytoskeleton 
dynamics, and a host of intracellular signalling pathways – just like PP1. However, unlike 
PP1, its regulation is fairly complex. PP2A exists in two forms; a heterodimeric core enzyme 
and a heterotrimeric holoenzyme. The core enzyme comprises a 36 kDa catalytic (C) and a 
scaffold (A) subunit, each having two (α and β) isoforms. The core enzyme in turn associates 
with a regulatory subunit from one of the four (B, B’, B’’, B’’’) subunit families; each family 
can have two to five isoforms encoded by individual genes with tissue-specific expression 
levels. For further details on PP2A core enzymes and holoenzymes, please see [15]. As 
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described above, OKA is an extremely potent inhibitor of the PP2AC subunit with an 
inhibitory constant of 0.1 nM, which suggests that OKA is approx. 100-fold more potent for 
PP2A compared to PP1 [37]. 
Based on the above, careful selection of the effective dose of OKA may enable 
selective inhibition of PP2A, without influencing PP1 phosphatase activity. It is noteworthy, 
however, that inhibitory doses were gained from cell-free in vitro assays with purified 
enzymes (sometimes catalytic subunits only); therefore, one should be careful when drawing 
strict conclusions from experiments wherein OKA was applied. Following this line of 
reasoning, some of the observations discussed in Section 3.1. could be attributed to inhibition 
of both PP1 and PP2A (see Fig. 1). 
 
5.1. PP2A regulates chondrogenesis in micromass cultures 
The first papers that aimed to explore the effects of PP2A inhibition on chondrogenesis 
by 20 nM OKA were published by our laboratory in 2001 and 2002. Besides significantly 
enhancing cartilage matrix formation, which could be attributed to PP2A inhibition, 
application of OKA interfered with the actin cytoskeleton and a considerably higher 
proportion of chondrogenic cells attained a rounded, chondroblast-like phenotype [40]. In 
fact, PP2A has been reported to mediate actin cytoskeleton reorganisation also in fibroblasts 
[45]. Another interesting finding was that treatment with OKA significantly stimulated the 
proliferation of chondrogenic cells; although the exact mechanism remains elusive, similar 
effects have been observed by others (reviewed in [46]). Moreover, inhibition of PP2A by 20 
nM OKA elevated the activity of PKA, and increased the phosphorylation of CREB in 
chicken limb bud-derived micromass cultures, suggesting that CREB was a common 
substrate for both the chondrogenesis-stimulating PKA and the inhibitory PP2A [47]. 
We have recently further dissected the involvement of PP2A in the regulation of in 
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vitro chondrogenesis and described for the first time that cyclic mechanical load reduced 
PP2A (and at the same time stimulated PKA) activity via a yet undetermined mechanism. 
Subsequently, the balance shifted to more strongly phosphorylated Sox9 and CREB 
transcription factors, and more pronounced nuclear localisation of both molecules could lie in 
the background of enhanced chondrogenic differentiation and matrix formation [48]. Based 
on these data, it is clear that PP2A can be one of the important mediators of mechanical 
stimuli during chondrogenic differentiation (Fig. 2). 
 
5.2. Other roles of PP2A in chondrocytes 
Fibroblast growth factor (FGF) is a central regulator of chondrocyte proliferation and 
differentiation; it inhibits chondrocyte cell division via the retinoblastoma (Rb) family 
members p107 and p130, which are essential regulators of the cell cycle [49]. The activity of 
Rb proteins is regulated by Ser/Thr phosphorylation; once hypophosphorylated, Rb proteins 
are activated and inhibit transcriptional activation via the E2F family of transcription factors. 
Conversely, phosphorylation by cyclin dependent kinases inactivates them, enabling cell 
cycle progression and cell proliferation to commence. Kolupaeva and co-workers described 
for the first time that the dephosphorylation of p107, which is a critical event in the FGF 
signalling pathway of chondrocytes (in rat chondrosarcoma cells) leading to cell cycle arrest, 
was mediated by PP2A [50]. Following up on that initial study, the same research group 
identified that the above effects could be attributed to the α isoform of the 55-kDa regulatory 
subunit (B55α) and that binding between B55α and p107 induced by FGF was a chondrocyte-
specific phenomenon [51]. Furthermore, they have also shown that activation of FGF 
signalling leads to dephosphorylation of the B55α subunit itself on specific Ser residues 
(Ser125, Ser266, and Ser294) that significantly increases the affinity of the PP2A–B55α 
holoenzyme to p107. They speculated that either another Ser/Thr PP (for example, PP1) or 
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PP2A itself could mediate B55α regulatory subunit dephosphorylation. Interestingly, 
although with a slightly different approach, another research team has reached the same 
conclusion concerning dephosphorylation of p107 by the PP2A–B55α holoenzyme [52]. In 
their model, FGF1 signalling activates p107 dephosphorylation via PP2A–B55α, leading to 
the formation of p107 complexes to target genes regulated in the process (Fig. 2). 
Parathyroid hormone-related peptide (PTHrP) is a well-known regulator of chondrocyte 
maturation. Acting through its G protein-coupled receptor, PTHrP can initiate downstream 
signalling that involves activation of Gs proteins, adenylate cyclase, and PKA, leading to 
blockage of chondrocyte maturation and hypertrophy [53]. MEF2 transcription factor is also 
an important element in the regulation of terminal differentiation of chondrocytes; it can 
induce the process by activating the transcription of Col10a1 [54]. MEF2 is regulated by 
HDAC4, a member of class II histone deacetylases. In general, histone acetylation by histone 
acetyltransferases stimulates transcription, whereas histone deacetylation mediated by 
HDACs leads to transcriptional repression. HDAC4 is known to be controlled by 
phosphorylation at specific Ser residues, rendering it to be associated with 14-3-3 scaffold 
proteins, which leads to loss of repression of MEF2 activity [55]. As an attempt to shed more 
light on this pathway, Kozhemyakina and co-workers identified the involvement of PP2A as 
the phosphatase that dephosphorylates and thus enables the nuclear translocation of HDAC4. 
They found that in sternal chondrocytes isolated from 18-day-old chicken embryos, PTHrP 
signals blocked chondrocyte maturation and hypertrophy by promoting dephosphorylation of 
HDAC4 at Ser246 mediated by PP2A; once dephosphorylated, HDAC4 could translocate 
into the nucleus and repress MEF2 activity [56] (Fig. 2). 
 
5.3. PP2A is differentially regulated in healthy and OA chondrocytes 
As discussed above, TGF-β1 stimulates the synthesis of cartilage ECM components 
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including proteoglycans and collagen type II and is therefore considered as a cartilage-
protective agent during inflammatory diseases such as OA. Lires-Deán and colleagues 
demonstrated that PP2A was differentially regulated in healthy and OA chondrocytes 
downstream of TGF-β1 [57]. They described that while TGF-β1 reduced the rate of apoptosis 
elicited by TNF-α and the PK inhibitor Ro31 in inflammatory chondrocytes, it was unable to 
do so in normal chondrocytes. Furthermore, while PP2A activity was not influenced by TGF-
β1 in OA-affected chondrocytes, a significant increase was observed in healthy chondrocytes, 
implicating that TGF-β1 utilises a downstream pathway that involves PP2A in these cells, 
which eventually leads to a significant decrease in the bcl-2/bax ratio, indicative of apoptotic 
stimuli [58]. The fact that pre-treatment with the PP2A-specific inhibitor IPP2A rescued 
normal chondrocytes from experimentally induced apoptosis and increased the ratio of bcl-
2/bax proteins suggests that PP2A could be a pivotal regulator of the anti-apoptotic effects of 
TGF-β1 (Fig. 2). These results indicate that selective modulation of the pathway that involves 
PP2A in inflammatory joint diseases such as OA is a promising target to be exploited. In 
summary, compared with PP1, more data are available pertaining to the role of PP2A in 
chondrogenesis and in healthy and inflammatory mature chondrocytes, but current 
knowledge is still far from being complete. Published data that support the function of PP2A 
in this field are shown in Fig. 2. 
 
6. Protein phosphatase 2B (PP2B, calcineurin, PP3) 
Considered as a crucial downstream effector of alterations in cytosolic Ca2+ 
concentration, calcineurin (CaN, PP2B) has been implicated in various biological processes 
including immune response, intracellular signalling pathways, and differentiation [59]. The 
CaN holoenzyme consists of a 60 kDa catalytic subunit (calcineurin A, CNA) which has at 
least 6 isoforms (Aα1, splice variant Aα2, Aβ1, splice variants Aβ2 and Aβ3, and Aγ), and a 19 
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kDa regulatory (calcineurin B or CNB) subunit which has 3 isoforms (B1, a splice variant of 
B1, and B2). Due to the fact that the autoinhibitory domain is localised at the CNA subunit, 
CaN becomes activated only upon association with Ca2+-calmodulin. The 
immunosuppressants FK506 (produced by the soil bacterium Streptomyces tsukubaensis) and 
cyclosporine A (CsA; isolated from the fungus Tolypocladium inflatum) exert their functions 
by inhibiting CaN after binding to immunophilins [60]. The inhibitory complexes FKBP12–
FK506 and cyclophilin A (CyPA)–CsA bind to the CNB-binding helical domain of the CNA 
subunit. They exert their immunosuppressant effects by CaN-mediated dephosphorylation of 
the nuclear factor of activated T cells (NFAT). Substrates for CaN possess a consensus 
sequence motif of PxIxIT [61]. For further details on CaN structure and function, please see 
[15]. 
Originally identified in T lymphocytes, the NFAT family of transcription factors 
consists of five members (NFATc1 through NFATc4 and NFAT5), each having multiple 
isoforms [62]. In unstimulated cells, hyperphosphorylated NFAT proteins are localized to the 
cytoplasm; however, activation of calcium-dependent signalling pathways may activate CaN, 
which dephosphorylates NFAT, thereby exposing the nuclear localization signal that elicits 
translocation to the nucleus [62]. NFAT has been shown to regulate transcription of many 
chondrocyte-specific genes including, among others, Col2a1 and Acan (reviewed in [63]). It 
was in that context that the first studies to reveal the presence and potential functions of CaN 
in chondrogenic cells and chondrocytes have been carried out. 
 
6.1. Effects of FK506 on chondrogenesis 
The first data pertaining to the effects of FK506 on chondrogenesis of the chondrogenic 
mouse embryonic teratocarcinoma cell line ATDC5 dates back to 2002 [60]. They found that 
ATDC5 cells exposed to 1 ng . mL–1 FK506 showed about a two-fold increase in Alcian blue 
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staining; however, CsA was unable to mimic the same effects even at higher concentrations. 
These results indicate that FK506 might have exerted its chondrogenesis-stimulating actions 
independent of CaN inhibition, albeit the authors did not aim to identify these mechanisms. 
Nakamura and colleagues also observed enhanced cartilage matrix accumulation, as well as 
increased expression of both collagen type II and type X following treatment with FK506 
using the same cell line, without significant alterations in transcriptional activity of Sox6 or 
Sox9 [64]. The authors concluded that FK506 may promote differentiation into the 
proliferating chondrocyte stage through a mechanism independent of Sox9 transcriptional 
activity, and they were also unable to establish a direct involvement of CaN for the 
promotion of in vitro chondrogenesis in ATDC5 cells by FK506. 
Following up on these initial results, Tateishi and co-workers established that FK506 
(administered at 1 µm . mL–1) was able to promote chondrogenesis of synovial stromal cell 
(SSC) pellets cultured in chondrogenic medium; this effect was further enhanced with co-
administration of BMP-2 and TGF-β1. Given that these two morphogens are known to 
mediate the Smad signalling pathway, the authors looked at whether FK506 interfered with 
the phosphorylation level of Smads. Indeed, levels of phospho-Smad1/5/8 and phospho-
Smad3, downstream of BMP-2 and TGF-β1, respectively, were significantly higher in 
FK506-treated cultures than those in non-treated cells. At the same time, inhibition of Smad 
signalling by Noggin and SB431542 abolished FK506-induced chondrogenic differentiation 
of SSCs [65]. These results indicate a regulatory role of CaN in chondrogenesis via mediating 
Smad phosphorylation. 
 
6.2. CaN is an important regulator of chondrogenic differentiation 
Although the above-discussed publications failed to establish a direct link between CaN 
and chondrogenesis, they nevertheless suggested a negative effect of CaN during 
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chondrogenesis. In contrast to these observations, Tomita and co-workers were the first to 
show that PP2B was a positive regulator in this process. They demonstrated that in the 
chondrocytic mesenchymal cell line RCJ3.1C5.18, as well as in murine embryonic limb bud-
derived micromass cultures, elevated cytosolic Ca2+ concentration elicited by ionomycin 
treatment enhanced chondrogenesis and matrix formation in a CaN-dependent manner; 
furthermore, the PP2B substrate NFAT4 was found to be hypophosphorylated in response to 
ionomycin. Furthermore, NFAT4 activation upregulated BMP-2 expression, which in turn 
induced chondrogenesis. Since the above changes could be prevented by the CaN inhibitor 
CsA or the BMP antagonist noggin, the authors concluded that CaN/NFAT4 signalling 
activates BMP-2 expression and induces in vitro chondrogenesis [66]; thus they provided 
evidence that the phosphatase involved in the BMP-2 signalling pathway could indeed be 
CaN, according to the assertions of Tateishi and colleagues [65].  
To further characterise the involvement of CaN in growth factor-mediated signalling 
pathways during chondrogenic differentiation, the same research group has shown that 
besides BMP-2, Ca2+-dependent signals also induce the expression of fibroblast growth 
factor-18 (FGF-18), an essential regulator of cartilage differentiation. They found that CaN 
and the CaN-dependent transcription factor NFAT4 were required for FGF-18 expression. 
FGF-18, in turn, represses noggin expression and thereby increases chondrocyte gene 
expression and chondrogenesis via BMP-dependent signalling [67]. In other words, FGF-18 
and BMP-2 can cooperatively promote chondrogenesis in a CaN-dependent manner (Fig. 3). 
The above findings established CaN as a positive regulator of chondrogenesis; 
however, in 2005 our laboratory was the first to demonstrate the connection between CaN 
activity and the master chondrogenic transcription factor Sox9. We found that CsA 
significantly reduced cartilage matrix formation in embryonic chicken limb bud-derived 
micromass cultures, and downregulated Sox9 expression. We also observed that oxidative 
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stress evoked by H2O2 had a detrimental effect on chondrogenesis that was at least partly 
mediated via inhibition of CaN and activation of ERK1/2. Moreover, CaN was found to 
influence the phosphorylation status of ERK1/2 and Sox9 in chicken micromass cultures; 
however, the exact mechanism has not been studied [26]. In a follow-up study, we observed a 
reciprocal regulation between alterations is cytosolic Ca2+ levels and CaN activity; while 
lower intracellular Ca2+ levels reduced CaN activity, application of A23187 Ca2+ ionophore 
elicited ambiguous results, suggesting the involvement of other factors in determining CaN 
activity. At the same time, inhibition of CaN by CsA reciprocally influenced cytosolic Ca2+ 
levels, and abolished the characteristic pattern in intracellular Ca2+ concentration required for 
chondrogenic differentiation in chicken micromass cultures [68]. Although it is unclear how 
CaN inhibition has led to disturbed Ca2+ homeostasis in chondrogenic cells, it nonetheless 
shows the important role of CaN during cartilage formation. More recently, we have shown 
that CaN can also be one of the downstream targets of pituitary adenylate cyclase activating 
polypeptide (PACAP) signalling in differentiating chondrocytes [48]. 
CaN was also demonstrated to be one of the downstream mediators of Wnt5a during 
chondrogenesis in mouse limb bud-derived micromass cultures. The Wnt signalling pathway 
plays an essential role during embryonic development; besides its pleiotropic effects, it also 
controls the differentiation of chondroprogenitor mesenchymal cells during chondrogenesis. 
While the downstream effectors of the canonical Wnts have been mapped, the signalling 
pathway of the non-canonical Wnt5a is less understood [69]. Bradley and Drissi has recently 
established that treatment of chondroprogenitor cells by Wnt5a enhanced chondrocyte 
maturation through activation of CaMK and CaN/NFAT-dependent induction of Sox9, with 
concurrent inhibition of nuclear factor-kappaB (NF-κB) [70]. The signalling pathways in 
which the involvement of CaN has been described to regulate chondrogenesis are 
summarised in Fig. 3. 
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6.4. CaN in mature chondrocytes 
Since CaN unequivocally proved to be an essential positive regulator of chondrogenesis 
in various in vitro models, attempts were made to assign roles for CaN in mature 
chondrocytes. van der Windt and colleagues undertook to investigate CaN as a potential 
signalling molecule to improve chondrocyte phenotype for cartilage repair. They found that 
CaN activity significantly increased during dedifferentiation and decreased during 
redifferentiation in human articular chondrocytes in vitro. Moreover, inhibition of CaN 
activity by FK506 upregulated chondrogenic marker genes (i.e. Col2a1, Acan, Sox9) via 
enhanced TGF-β1 expression in dedifferentiated cells, suggesting a negative regulatory role 
for CaN in maintaining the mature chondrocyte phenotype in chondrocytes [71]. 
 
6.5. CaN in pathological conditions of cartilage 
To exploit the potentially protective effects of CaN, several research groups have 
attempted to shed more light on the possible role of CaN in the pathogenesis of OA. The 
favourable effects of CsA on adjuvant-induced arthritis in female rats have long been known 
[72]; however, these effects have first been attributed to blockade of T lymphocyte activation 
and subsequent reduction in pro-inflammatory cytokine (mainly IL-1β) release. To establish 
a role for CaN in inflammatory chondrocytes, Little and colleagues undertook to analyse the 
effects of CsA on aggrecan catabolism mediated by matrix metalloproteinases (MMPs) in a 
model that mimics the early stages of OA [73]. They demonstrated that CsA inhibited 
aggrecanase-mediated proteoglycan catabolism elicited by administration of IL-1β in bovine 
articular cartilage explants; CsA was also found to downregulate several ECM catabolic 
factors such as ADAMTS4, ADAMTS5, MMP-13. The authors concluded that CsA may 
represent an effective therapeutic tool for degenerative joint diseases, without providing 
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implications for the involvement of CaN. 
It was not until 2007 that Yoo and co-workers identified that link. They showed 
significantly higher levels of the catalytic subunit of CaN (CNA) in inflammatory 
chondrocytes, and that CsA was able to attenuate NO, MMP-1 and MMP-3 production. 
Furthermore, CsA treatment increased the levels of Col2a1 and TGF-β, indicative of an 
augmented anabolic response. Since similar response was observed by using the natural CaN 
antagonist calcineurin binding protein 1, the authors speculated that CaN is a critical 
component in the catabolic and anabolic activities of inflammatory chondrocytes [74]. 
van der Windt and colleagues reached the same conclusions relating to the role of CaN 
in mediating anabolic and catabolic responses of chondrocytes, although from a different 
approach. It has long been known that during OA, the osmolality of the cartilage ECM 
brought about by proteoglycan depletion and collagen degradation changes from 350–480 
mOsm to 280–350 mOsm [75]. In their study, they observed a significant upregulation of the 
chondrogenic marker genes Col2a1, Acan, and Sox9 when OA-affected human chondrocytes 
were cultured at 380 mOsm with concurrent inhibition of CaN by FK506. At the same time, 
catabolic factors (MMPs, ADAMTS) and terminal differentiation markers (Col10a1, alkaline 
phosphatase) were repressed. Their results indicate that CaN inhibition at physiological 
tonicity increases the expression of anabolic markers and downregulates hypertrophic and 
catabolic markers [76], which perfectly aligns with the observations of other groups 
discussed above. 
By further analysing the effects of CaN inhibition by FK506 on anabolic and catabolic 
markers of osteoarthritic chondrocytes in 2D and 3D in vitro cultures, as well as an in vivo rat 
model of OA, the same research group carried out further experiments. Besides reproducing 
their own results relating to induction of anabolic and reduction of catabolic ECM marker 
gene expressions following treatment of OA chondrocytes by FK506, they also reported that 
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inhibition of CaN activity by FK506 treatment in vivo reduced OA-like responses (i.e. 
cartilage ECM degradation, macrophage activation, osteophyte formation) in articular joint 
tissues. As a main conclusion, the authors implicate CaN as an interesting target for future 
therapeutic management of OA [77]. 
In summary, PP2B is known to be involved in multiple aspects of chondrogenesis, and 
it also plays an important role in the balance between anabolic and catabolic changes in 
mature chondrocytes. Fig. 3 depicts the known functions of CaN during chondrogenesis, 
whereas Fig. 4 summarises its roles in mature and/or OA-affected chondrocytes. 
 
7. PP4, PP5, and PP6 have not been studied in chondrogenesis 
Apart from PP1, PP2A, and PP2B, the potential roles of other phosphoprotein 
phosphatases (PP4, PP5 and PP6) have not been investigated either in differentiating or 
mature chondrocytes. PP4 (also known as PPX) is closely related to PP2A in that it also 
consists of catalytic and regulatory subunits, and it also forms heterodimeric core enzymes 
and heterotrimeric holoenzymes. An essential phosphatase in all eukaryotic species, PP4 has 
been reported to be involved in centrosome duplication, apoptosis, and DNA repair; regulates 
the JNK pathway; and mediates the effects of TNF-α [78]. In spite of its fundamental roles 
and the fact that is has been described more than 20 years ago [79], PP4 has not previously 
been shown either in differentiating or in mature chondrocytes. PP4 is known to govern 
differentiation of neural stem and progenitor cells, furthermore Smek, a regulatory subunit of 
PP4 has been recently demonstrated to play an important role in histone deacetylation and 
silencing of the Wnt-responsive gene brachyury in embryonic stem cells [80]. As already 
discussed, the Wnt pathway is an essential regulator of chondrogenesis; in particular, Wnt5a 
enhances chondrocyte maturation in a CaN-dependent manner [70]. Lyu and colleagues 
suggested that a Smek-containing PP4 complex represses the transcription of Wnt-responsive 
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genes through histone deacetylation, and that this complex is essential for the maintenance of 
embryonic stem cell pluripotency [80]. Following this line of reasoning, it would be 
interesting to analyse whether PP4 regulates chondrogenesis via modulation of Wnt 
signalling. 
Originally described in 1994, PP5 is a rather exotic phosphatase in that it is encoded by 
a single gene in all eukaryotic organisms, and that the regulatory and catalytic domains are 
contained within a solitary polypeptide [81]. Expressed in all tissues examined, PP5 regulates 
a diverse array of functions including proliferation, differentiation, migration, and stress-
induced signalling [15]. Still, no studies have been conducted to assign specific roles to this 
PP in differentiating or mature chondrocytes. According to the paper of Chen and co-
workers, PP5 negatively regulates embryonic stem cell differentiation by maintaining Nanog 
expression through the inhibition of ERK signalling [82]. Nanog has been reported to be 
expressed also in chondrogenic micromass cultures [83]; therefore, it would be interesting to 
find a connection between Nanog expression, PP5, and chondrogenic differentiation. 
Furthermore, since PP5 is known to mediate stress-induced signalling, it might have 
important implications in degenerative cartilage disorders such as OA. This theory, however, 
is yet to be confirmed. 
The catalytic subunit of PP6, another essential phosphatase, is also closely related to 
that of PP2A. PP6 is described to form a heterotrimeric holoenzyme that consists of a 
catalytic subunit, a Sit4-related scaffold subunit, and an ankyrin repeat-containing subunit as 
a regulatory subunit. Although first described in 1989 [84], relatively little is known about 
this enzyme except for its role in progression through the cell cycle [16]. Further studies are 
needed to characterise specific roles of PP6 in chondrocytes. 
 
8. Conclusions and perspectives 
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Although the number of genes that encode the catalytic subunits of PPs is much smaller 
compared to the number of genes that encode Ser/Thr PKs, current knowledge relating to the 
function of PPs is scarce, especially in the field of chondrogenesis. The combinatorial nature 
of PPs and the resultant complexity could have hindered research progress in this field; 
indeed, the wide range of different regulatory subunits and other interacting proteins that can 
associate with PP1 or PP2A catalytic subunits confer different substrate specificity, 
subcellular localisation, and regulation, eliciting sometimes opposing effects on signalling 
pathways. Besides the enormous complexity of PP1 and PP2A holoenzymes, there are some 
other unique features of PPs that hamper their studies. For instance, levels of PP catalytic 
subunits tend to be relatively constant in cells and resist alteration by either overexpression or 
knockdown by small interfering RNA techniques to preserve function. Furthermore, since 
PPs possess a robust catalytic activity, even a small quantity of the functional protein is 
sufficient to exert substantial effects [16]. 
Based on the above specific features, current understanding of PP function in 
differentiating and mature chondrocytes is far from complete. There are major unanswered 
questions regarding the specific roles for every PP family or subfamily; for example, how 
exactly do they balance the effects of PKs during chondrogenesis, and what functions do they 
play in pathological processes of cartilage. One of the major challenges is to identify the 
substrate proteins for PPs; in other words, to determine which phosphatase is responsible for 
dephosphorylation of a given phospho-protein in differentiating chondrocytes. Because of the 
obstacles outlined above, the classic approach that employs the application of more or less 
selective PP inhibitors and/or overexpression/gene silencing will likely fail. 
Phosphoproteomics may provide a versatile tool in assigning phosphatases to substrates in 
chondrocytes. This approach has been successfully applied to detect phosphorylation pattern 
following mechanical stretching in chondrosarcoma cells [85]. By better exploiting the 
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sensitivity of this approach, a more detailed discovery of PP substrates is envisaged. 
 
8.1. Regulation of ion channel functions and Ca2+ homeostasis by PPs 
Among the most interesting candidate targets for PPs are ion channels. Although 
considered as an archetypal non-excitatory cell, the chondrocyte employs a full complement 
of a great variety of ion channels to maintain cellular ion homeostasis (for a review, see [86]). 
Moreover, not only are they essential components of maintaining ion homeostasis of mature 
chondrocytes but they are also required for chondrogenic differentiation. Various ion 
channels including TRPV4 [87]; the ionotropic purinergic receptor P2X4 [7, 88]; chloride 
channels [89]; voltage-gated sodium and potassium channels [8]; and voltage-dependent Ca2+ 
channels [5] have been described to be involved in chondrogenesis. Besides the important 
role of cytosolic Ca2+ in differentiating chondroprogenitors and subsequent activation of Ca2+ 
dependent signalling cascades such as PKC or PP2B, it would be intriguing to investigate if 
phosphorylation in turn mediates cytosolic Ca2+ levels via modulation of ion channel activity 
in chondrocytes.  
In 1989, Armstrong postulated that there was a close interaction between CaN, PKA, 
and dihydropyridine-sensitive voltage-gated Ca2+ channels (i.e. CaV1.1) in which CaN, by 
dephosphorylating the Ca2+ channel, would inactivate it and the reduced Ca2+ influx would in 
turn deactivate CaN [90]. This hypothesis was confirmed with de facto electrophysiological 
data by Fomina and Levitan who demonstrated that in rat pituitary lactotrop cells inhibition 
of CaN activity by CsA has led to reduced ionic currents via voltage-gated Ca2+ channels 
[91]. Since then, CaN has been shown to modulate a number of ion channels including 
inhibition of the arachidonate-regulated Ca2+ channels (ARC channels that are closely related 
to the store-operated CRAC channel Orai proteins) [92]; the intracellular Ca2+ release 
channels inositol trisphosphate receptor (IP3R) and ryanodine receptor (RyR) [61]; or the 
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vanilloid receptor TRPV1 [93]. In smooth muscle cells, PP1 was described to increase the 
open probability of the large-conductance, voltage- and Ca2+-gated K+ (BKCa) channel; in 
contrast, PP1 inhibited the A-type K+ channel 19-pS in mouse colon cells through its fast 
inactivation mechanism. Apart from potassium channels, PP1 has been reported to be 
involved in activating and/or deactivating L-type Ca2+ channels (for a review, see [94]). 
PP2A has also been implicated to regulate L-type Ca2+ channel and BKCa K+ channel 
function [94]. 
However, none of these interactions have been demonstrated either in differentiating or 
in mature chondrocytes. In particular, our own laboratory supplied indirect data to support the 
idea that CaN can in fact influence Ca2+ ion channel activities during chondrogenesis; 
application of CsA to differentiating chondroprogenitors eliminated the peak in basal 
cytosolic Ca2+ concentration, suggesting an important regulatory role for CaN [68]. Future 
studies are required to elucidate the precise involvement of CaN and other PPs in 
dephosphorylating specific ion channels during the course of chondrogenesis. 
We have recently documented that in parallel to Ca2+ influx, Ca2+ release from internal 
Ca2+ stores and subsequent store refilling through store-operated Ca2+ entry (SOCE) mediated 
by Orai and STIM molecules was also required for chondrogenesis to take place [5]. 
Although considerable research has been done in that field during the last couple of years, the 
posttranslational regulation of the molecules that orchestrate SOCE is still elusive. It has only 
recently been shown that CaN, associated with kinase suppressor of ras 2 (KSR2), was 
indispensable for SOCE; CaN inhibition impaired formation of STIM1/Orai1 puncta and 
cytoskeleton organization [95].  
While long-term sustained Ca2+ signals are undoubtedly essential for chondrogenic 
differentiation, high-frequency Ca2+ oscillations mediated by voltage-dependent K+ and Ca2+ 
channels, as well as SOCE, are also of particular importance [5, 8]. Pulsatile changes in local 
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cytosolic Ca2+ concentration have long been known to modulate a host of cellular processes 
including gene transcription. NFAT is one of the oscillation-sensitive transcription factors; in 
fact, besides CREB [96], NFAT has been proposed to be one of the key mediators and 
molecular decoders of information encoded in the frequency of Ca2+ spikes [97]. Given that 
CaN is responsible for the Ca2+-dependent dephosphorylation and nuclear translocation of 
NFAT, it seems plausible that Ca2+-dependent activation of NFAT is attributable to CaN. In 
contrast, stimulation with agonist concentrations that elicited oscillatory Ca2+ signals failed to 
increase CaN activity [92]. Nevertheless, CaN activation is clearly context-dependent and 
differentiating chondroprogenitors might represent a cell type in which CaN could be one of 
the key molecular regulators of cytosolic Ca2+ fluctuations. Taken together, it would be 
interesting to link CaN and other phosphatases to the tight control of SOCE, Ca2+ influx 
through plasma membrane ion channels, and the dynamic changes of global Ca2+ homeostasis 
during chondrogenesis. 
Such a link has been established in a recently published paper by Lin and colleagues 
[98]. They documented that Ca2+ influx through the T-type voltage-operated Ca2+ channel 
CaV3.2 was essential for chondrogenesis in tracheal cartilage (but not in articular cartilage), 
without modulating the proliferation of differentiating mesenchymal cells. They described 
that Ca2+ influx through CaV3.2 activated the CaN/NFAT signalling and upregulated cartilage 
ECM-specific marker genes such as Sox9, Acan and Col2a1, since treatment with CsA 
eliminated the observed effects. Moreover, they identified an NFAT-binding motif (TTTCC) 
in the mouse Sox9 promoter, which provides direct evidence for the first time that the Ca2+–
CaN–NFAT axis can indeed upregulate Sox9 expression during chondrogenesis [98]. These 
results are in a perfect agreement with our own data that T-type voltage-dependent Ca2+ 
channels, including CaV3.2, were expressed in chondrifying micromass cultures, and that 
blockade of these channels detrimentally affected chondrogenesis [5]. 
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8.2. Osteoarthritis and protein phosphatases – candidate drug targets? 
As discussed above, PP1, PP2 and PP2B have all been studied in the context of OA. It 
must be noted, however, that available data are surprisingly scarce, and thus we are only at 
the beginning to understand the role of PPs during the pathogenesis of OA. Nevertheless, 
despite the small number or relevant studies, it seems to be the case that PPs, CaN in 
particular, appears to be an interesting target for future therapeutic management of OA. 
Given the pleiotropic effects and essential functions of PPs in virtually every cell in the body, 
it will be challenging to find solutions that offer targeted delivery and reduce undesirable side 
effects. For example, chronic systemic treatment with the CaN inhibitor FK506 is known to 
have adverse effects on many tissues and organs including nephrotoxicity and neurotoxicity 
[99]. At the same time, local intra-articular delivery of FK506 may increase the risk of 
iatrogenic arthritis [77]. Thus, there is a pressing need to develop novel, more specific drugs 
that target PPs in a context-dependent manner in OA-affected articular cartilage, ideally 
without adverse effects that would advance disease progression. Obviously, these proteins are 
very difficult to target for drug development. The challenge should be easier for PP1 and 
PP2A by developing regulatory subunit-specific inhibitors that would exert their disease-
modifying effects in OA-affected cartilage only. Local (intra-articular) administration of such 
novel drugs may facilitate efficacy and at the same time reduce the risk of systemic adverse 
effects. 
In conclusion, the published scientific data reviewed in this paper clearly indicate that 
PPs are indeed important regulators of differentiating and mature chondrocytes, with 
important implications for disease-specific functions. Yet there are many unanswered 
questions. For protein phosphorylation to be reversible, a delicate balance between PKs and 
PPs must exist at all times. While multiple PKs involved in the highly complex signal 
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transduction and other physiological systems that control the molecular machinery of 
chondrogenesis are confirmed, only a very small portion of PPs have been mapped. As 
opposed to PKs where at least a few important functions of all major families have been 
established, PPs have only been described in a much more restricted context. Clearly there is 
an urgent need for studies with a primary aim to elucidate novel aspects and assign novel 
functions to the neglected yet essential components of reversible protein phosphorylation 
during chondrogenesis. 
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Table 1. Roles of the main PK families in controlling the key steps in chondrogenesis and 
signalling pathways in chondrocytes. 
 
PK family Role(s) Reference* 
cyclic AMP dependent 
protein kinase (PKA) 
Positive regulator of chondrogenesis; 
mediates BMP-2 signalling and 
phosphorylates CREB; modulates N-
cadherin expression via activating PKCα 
[17, 18, 20] 
Protein kinase C (PKC) 
isoenzymes 
Positive regulators of chondrogenesis; 
mediate the expression of cell adhesion 
molecules, actin cytoskeleton 
reorganisation, modulates MAPK 
pathway 
[6, 19] 
Mitogen-activated protein 
kinases (MAPKs) 
 [3] 
1. Extracellular signal-
regulated kinase 
(ERK1/2) 
Negative or positive regulator of 
chondrogenesis, depending on 
embryological origin, differentiation 
stage, and concurrently active other 
pathways; mediates the effects of BMP-
2, FGF, IGF-1, etc. 
[20, 23, 25] 
2. p38 Positive regulator of chondrogenesis; 
mediates the effects of BMP-2, TGF-β2, 
etc. 
[22] 
3. c-jun N-terminal 
kinase (JNK) 
Positive or negative regulator of 
chondrogenesis; mediates the effects of 
Gas6; modulates miR-34a  
[27, 28] 
Ca2+/calmodulin-dependent 
protein kinases (CaMKs) 
CaMKII is involved in 
mechanotransduction; modulate 
hypertrophic gene expression 
[31, 32] 
 
*For simplicity, only a few selected references are shown. Where available, the reader is 
referred to recent relevant review articles for further details 
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Figures 
 
Fig. 1. PP1 appears to play a negative regulatory role in differentiating chondrocytes. 
Available data suggest an inhibitory function for PP1; it dephosphorylates CREB; activates 
ERK1/2 signalling; attenuates the JNK pathway; and dephosphorylates TβRI, and thus blocks 
the TGF-β–Smad7–Col2a1 pathway in chondrocytes. For further details and references, 
please see text. Noteworthy, however, that depending on the concentration, OKA is a potent 
inhibitor also of PP2A, therefore one should be cautious when drawing conclusions from 
these potentially ambiguous results. (CREB-1, cAMP response element binding protein-1; 
COX-2, cyclooxygenase-2; ERK1/2, extracellular signal-related kinase 1/2; GADD34, 
growth arrest and DNA damage protein-34; OKA, okadaic acid; SAPK/JNK, stress-activated 
protein kinase/jun N-terminal kinase; TGF-β, transforming growth factor-beta; TβRI, TGF-β 
receptor I) 
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Fig. 2. PP2A exerts a negative role in chondrogenesis and in differentiating chondrocytes. 
Inhibition of PP2A activity by 20 nM OKA (or IPP2A, or cyclic mechanical load) promotes 
chondrogenesis and cartilage ECM production, and enhances proliferation. PP2A reduces 
Sox9, CREB and PP2A activity during chondrogenesis. PP2A is involved in the downstream 
signalling of FGF1, TGF-β, and PTHrP. The 55-kDa regulatory subunit (B55α) is known to 
be involved in certain pathways. PP2A seems to negatively regulate maturation and 
hypertrophy by dephosphorylating HDAC4. PP2A is also reported to regulate the cell cycle 
via p107 and modulate apoptosis. For further details and references, please see text. (CREB, 
cAMP response element binding protein; ERK1/2, extracellular signal-related kinase 1/2; 
FGF1, fibroblast growth factor-1; HDAC4, histone deacetylase-4; MEF2, myocyte enhancer 
factor-2; OKA, okadaic acid; PKA, protein kinase-A; PTHrP, parathyroid hormone related 
peptide; TGF-β, transforming growth factor-beta; TβRI, TGF-β receptor I) 
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Fig. 3. CaN is an important chondrogenesis-stimulating regulator during chondrogenesis. 
Responses to multiple soluble factors including Wnt-5A, PACAP1–38, FGF-18, and BMP-2 
are known to be mediated via CaN. Local or global increases in cytosolic [Ca2+] are also 
required for CaN activation. CsA and ROS (H2O2) can inhibit CaN activity. One of the main 
downstream targets is NFAT-4 which, after CaN-mediated dephosphorylation, translocates 
into the nucleus and upregulates cartilage-specific genes. CaN also activates Sox9, but 
inhibits the ERK1/2 pathway. CaN is implicated to regulate ion channels and thus modulate 
ion conductivities. References and further details are in the main text. (BMP-2, bone 
morphogenic protein-2; CsA, cyclosporine A; ERK1/2, extracellular signal-related kinase 
1/2; FGF-18; fibroblast growth factor-18; NFAT-4, nuclear factor of activated T 
lymphocytes-4; NF-κB, nuclear factor-kappa B; PACAP, pituitary adenylate cyclase 
activating polypeptide; ROS, reactive oxygen species) 
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Fig. 4. CaN negatively regulates the chondrocyte phenotype in mature or OA-affected 
chondrocytes. In contrast to chondrogenesis, CaN activates catabolic enzymes including 
ADAMTS, MMP, as well as NO, and blocks transcription of cartilage-specific genes (such as 
Col2a1) and TGF-β1. See text for more detailed explanation and relevant references. 
(ADAMTS, “A Disintegrin And Metalloproteinase with Thrombospondin Motifs”; CsA, 
cyclosporine A; MMP, matrix metalloprotease; NO, nitrogen oxide; TGF-β1, transforming 
growth factor beta-1; TβRI, TGF-β receptor I) 
 
 
